Novel Myocardial Markers GADD45G and NDUFS5 Identified by RNA

Total Page:16

File Type:pdf, Size:1020Kb

Novel Myocardial Markers GADD45G and NDUFS5 Identified by RNA Iwahana et al. BMC Cardiovascular Disorders (2020) 20:116 https://doi.org/10.1186/s12872-020-01396-2 RESEARCH ARTICLE Open Access Novel myocardial markers GADD45G and NDUFS5 identified by RNA-sequencing predicts left ventricular reverse remodeling in advanced non-ischemic heart failure: a retrospective cohort study Togo Iwahana1, Sho Okada1* , Masato Kanda1, Motohiko Oshima2, Atsushi Iwama2, Goro Matsumiya3 and Yoshio Kobayashi1 Abstract Background: Left ventricular reverse remodeling (LVRR) has been detected in non-ischemic dilated cardiomyopathy (NIDCM) patients following optimal treatment. However, its prediction with only conventional modalities is often difficult. This study sought to examine whether RNA sequencing (RNA-seq) of myocardium tissue samples could predict LVRR in NIDCM. Methods: A total of 17 advanced NIDCM patients with left ventricular ejection fraction (LVEF) below 30% who underwent cardiac biopsy from Left ventricle (LV) were prospectively recruited. They received optimal treatment and followed with echocardiogram every 6 months. Based on LVRR status after 12 months of treatment, patients were divided into the reverse remodeling (RR) or non-RR group. Tissue samples were analyzed by RNA-seq, and a functional analysis of differentially expressed genes was carried out. Results: There were eight and nine patients in the RR and non-RR groups, respectively. No difference was found in age, sex, disease duration, LV end-diastolic diameter, and LVEF between the two groups. There were 155 genes that were differentially expressed between the two groups. Nicotinamide adenine dinucleotide ubiquinone oxidoreductase subunit (NDUF)S5 and Growth arrest and DNA-damage-inducible protein (GADD)45G, along with several genes related to the mitochondrial respiratory chain and ribosome, were significantly downregulated in the RR as compared to the non-RR group. Conclusion: GADD45G and NDUFS5 are potential biomarkers for LVRR in patients with advanced NIDCM. Keywords: NIDCM, LVRR, RNA-seq, NDUFS5, GADD45G * Correspondence: [email protected] 1Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan Full list of author information is available at the end of the article © The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. Iwahana et al. BMC Cardiovascular Disorders (2020) 20:116 Page 2 of 12 Background of the LV at Chiba University Hospital from September Heart failure has a complex etiology and is associated 2014 to May 2016 were included in the study. Exclusion with various conditions, and is a major cause of adult criteria were as follows: (i) heart failure with ischemic mortality. In particular, non-ischemic dilated cardiomy- etiology (defined as past history of myocardial infarction opathy (NIDCM)—which is characterized by left ven- or significant stenosis in the main branches of coronary tricular (LV) dilation and a severely reduced LV ejection arteries); (ii) inflammatory or infiltrative heart disease fraction (LVEF) without coronary artery disease—is including myocarditis, sarcoidosis, or amyloidosis; (iii) often refractory to established drugs such as β-blockers, other secondary or metabolic cardiomyopathies such as angiotensin-converting enzyme inhibitors, and angioten- neuromuscular disease and alcoholic cardiomyopathy; sin II receptor blockers and to cardiac resynchronization (iv) dependence on hemodialysis; and (v) age younger therapy (CRT). Therefore, NIDCM often requires heart than 20 years or older than 65 years. transplantation or ventricular assist device (VAD) im- plantation. However, the former is available only to a Patient follow-up limited number of patients, whereas the latter is associ- Prior to myocardial biopsy, all patients underwent blood ated with complications like stroke, bleeding, and infec- sample collection, echocardiogram, and right heart tion that can be fatal during the long waiting period for catheterization. After myocardial biopsy, patients contin- transplantation [1]. ued to receive optimal treatment including guideline- On the other hand, many NIDCM patients show re- directed medical therapy with β-blockers and renin- covery of cardiac function after optimal pharmacological angiotensin blockers and CRT. Patients were followed or device therapy [2, 3]. This phenomenon, known as for 6 to 12 months, with echocardiogram performed at LV reverse remodeling (LVRR), is associated with im- each follow up; they were then divided into the reverse proved clinical outcomes. Accordingly, several indices remodeling (RR) and non-RR groups according to posi- have been identified as predictors of LVRR and heart tive or negative LVRR status, respectively. LVRR was failure, including blood biomarkers like suppression of defined as (i) LVEF improvement of > 10% in absolute tumorigenesis-2 and galectin-3 [4–8], late gadolinium value, and (ii) LVEF > 30%. enhancement by cardiac magnetic resonance imaging [9], cardiac fibrosis and cardiomyocyte hypertrophy by RNA extraction and cDNA library preparation histopathological examination [10, 11], and washout rate LV myocardium samples were collected at the time of in meta-iodobenzylguanidine myocardial scintigraphy cardiac catheter examination or open heart surgery, in- [12]. However, conventional modalities cannot accur- cluding for VAD implantation and valve replacement. ately predict the occurrence of LVRR. Samples were immediately treated with RNAlater RNA Analyzing myocardial gene expression can be more stabilization reagent (Qiagen, Valencia, CA, USA) and useful for this purpose. Several studies have demon- stored at − 20 °C. Total RNA was extracted using mir- strated a clear correlation between myocardial expres- Vana miRNA Isolation kit (Life Technologies, Carlsbad, sion of certain mRNAs or micro (mi)RNAs and LVRR in CA, USA) according to the manufacturer’s instructions, NIDCM patients by quantitative reverse transcription and cDNA libraries were generated using a NEBNext PCR [13, 14]. Moreover, RNA sequencing (RNA-seq) Ultra RNA Library Prep kit (New England BioLabs, and next generation sequencing (NGS)—which enables Beverly, MA, USA). Sequencing was performed using a higher throughput and greater accuracy in the evaluation HiSeq1500 system (Illumina, San Diego, CA, USA) with of gene expression than microarray analysis [15]—is in- a single-read sequencing length of 60 bp. creasingly used in clinical settings [16]. Previous NGS studies have revealed differences in gene expression pro- RNA-seq data analysis files between ischemic and non-ischemic cardiomyop- TopHat v.1.3.2 with default parameters was used to map athy [17, 18] or pre- and post VAD support [19–21]. sequences against the UCSC/hg19 reference genome. However, there have been no studies using comprehen- Gene expression level was quantified using Cufflinks sive transcriptome analysis to examine specific genes re- v.2.0.2 [22, 23] as fragments per kilobase of exon per lated to LVRR. The present study therefore aimed to million fragments (FPKM) mapped reads. In the present identify factors that can predict LVRR occurrence by study, miRNAs and genes expressed at low levels (FPKM RNA-seq. < 1 in all samples) were eliminated. To identify novel biomarkers that predict the occurrence of LVRR, we car- Methods ried out sensitivity, specificity, and receiver operating Patient selection characteristic (ROC) curve analyses for each differentially Patients with advanced NIDCM whose LVEF was < 30% expressed gene (DEG). Functional annotation was per- by echocardiogram and who underwent cardiac biopsy formed using the Database for Annotation, Visualization, Iwahana et al. BMC Cardiovascular Disorders (2020) 20:116 Page 3 of 12 and Integrated Discovery [24–26]. Gene expression pro- artery disease or other secondary or specific cardiomy- files of two groups were compared by principal compo- opathies were analyzed. LV myocardial samples were ob- nent analysis (PCA). RNA-sequencing data was deposited tained by transcatheter biopsy for four patients, by in the DNA Data Bank of Japan (accession number needle biopsy during aortic valve replacement surgery PRJDB5368). for three patients, or during VAD implantation for 10 patients. Quantitative real-time PCR Patients were divided into RR (n = 8) and non-RR (n = When the same cDNAs as for RNA-seq were available, 9) groups based on the findings of a follow-up echocar- quantitative real-time PCR (qPCR) was performed on a diogram. There were no differences between the two Light Cycler
Recommended publications
  • The Genomic Structure and Expression of MJD, the Machado-Joseph Disease Gene
    J Hum Genet (2001) 46:413–422 © Jpn Soc Hum Genet and Springer-Verlag 2001 ORIGINAL ARTICLE Yaeko Ichikawa · Jun Goto · Masahira Hattori Atsushi Toyoda · Kazuo Ishii · Seon-Yong Jeong Hideji Hashida · Naoki Masuda · Katsuhisa Ogata Fumio Kasai · Momoki Hirai · Patrícia Maciel Guy A. Rouleau · Yoshiyuki Sakaki · Ichiro Kanazawa The genomic structure and expression of MJD, the Machado-Joseph disease gene Received: March 7, 2001 / Accepted: April 17, 2001 Abstract Machado-Joseph disease (MJD) is an autosomal relative to the MJD gene in B445M7 indicate that there are dominant neurodegenerative disorder that is clinically char- three alternative splicing sites and eight polyadenylation acterized by cerebellar ataxia and various associated symp- signals in MJD that are used to generate the differently toms. The disease is caused by an unstable expansion of the sized transcripts. CAG repeat in the MJD gene. This gene is mapped to chromosome 14q32.1. To determine its genomic structure, Key words Machado-Joseph disease (MJD) · 14q32.1 · we constructed a contig composed of six cosmid clones and CAG repeat · Genome structure · Alternative splicing · eight bacterial artificial chromosome (BAC) clones. It spans mRNA expression approximately 300kb and includes MJD. We also deter- mined the complete sequence (175,330bp) of B445M7, a human BAC clone that contains MJD. The MJD gene was found to span 48,240bp and to contain 11 exons. Northern Introduction blot analysis showed that MJD mRNA is ubiquitously expressed in human tissues, and in at least four different Machado-Joseph disease (MJD) is an autosomal dominant sizes; namely, 1.4, 1.8, 4.5, and 7.5kb.
    [Show full text]
  • Low Abundance of the Matrix Arm of Complex I in Mitochondria Predicts Longevity in Mice
    ARTICLE Received 24 Jan 2014 | Accepted 9 Apr 2014 | Published 12 May 2014 DOI: 10.1038/ncomms4837 OPEN Low abundance of the matrix arm of complex I in mitochondria predicts longevity in mice Satomi Miwa1, Howsun Jow2, Karen Baty3, Amy Johnson1, Rafal Czapiewski1, Gabriele Saretzki1, Achim Treumann3 & Thomas von Zglinicki1 Mitochondrial function is an important determinant of the ageing process; however, the mitochondrial properties that enable longevity are not well understood. Here we show that optimal assembly of mitochondrial complex I predicts longevity in mice. Using an unbiased high-coverage high-confidence approach, we demonstrate that electron transport chain proteins, especially the matrix arm subunits of complex I, are decreased in young long-living mice, which is associated with improved complex I assembly, higher complex I-linked state 3 oxygen consumption rates and decreased superoxide production, whereas the opposite is seen in old mice. Disruption of complex I assembly reduces oxidative metabolism with concomitant increase in mitochondrial superoxide production. This is rescued by knockdown of the mitochondrial chaperone, prohibitin. Disrupted complex I assembly causes premature senescence in primary cells. We propose that lower abundance of free catalytic complex I components supports complex I assembly, efficacy of substrate utilization and minimal ROS production, enabling enhanced longevity. 1 Institute for Ageing and Health, Newcastle University, Newcastle upon Tyne NE4 5PL, UK. 2 Centre for Integrated Systems Biology of Ageing and Nutrition, Newcastle University, Newcastle upon Tyne NE4 5PL, UK. 3 Newcastle University Protein and Proteome Analysis, Devonshire Building, Devonshire Terrace, Newcastle upon Tyne NE1 7RU, UK. Correspondence and requests for materials should be addressed to T.v.Z.
    [Show full text]
  • Gene Expression Profiling Analysis of Lung Adenocarcinoma
    Brazilian Journal of Medical and Biological Research (2016) 49(3): e4861, http://dx.doi.org/10.1590/1414-431X20154861 ISSN 1414-431X 1/11 Gene expression profiling analysis of lung adenocarcinoma H. Xu1,2,J.Ma1,J.Wu1, L. Chen1,F.Sun1,C.Qu1, D. Zheng1 and S. Xu1 1Department of Thoracic Surgery, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China 2Laboratory of Medical Genetics, Harbin Medical University, Harbin, Heilongjiang, China Abstract The present study screened potential genes related to lung adenocarcinoma, with the aim of further understanding disease pathogenesis. The GSE2514 dataset including 20 lung adenocarcinoma and 19 adjacent normal tissue samples from 10 patients with lung adenocarcinoma aged 45-73 years was downloaded from Gene Expression Omnibus. Differentially expressed genes (DEGs) between the two groups were screened using the t-test. Potential gene functions were predicted using functional and pathway enrichment analysis, and protein-protein interaction (PPI) networks obtained from the STRING database were constructed with Cytoscape. Module analysis of PPI networks was performed through MCODE in Cytoscape. In total, 535 upregulated and 465 downregulated DEGs were identified. These included ATP5D, UQCRC2, UQCR11 and genes encoding nicotinamide adenine dinucleotide (NADH), which are mainly associated with mitochondrial ATP synthesis coupled electron transport, and which were enriched in the oxidative phosphorylation pathway. Other DEGs were associated with DNA replication (PRIM1, MCM3, and RNASEH2A), cell surface receptor-linked signal transduction and the enzyme-linked receptor protein signaling pathway (MAPK1, STAT3, RAF1, and JAK1), and regulation of the cytoskeleton and phosphatidylinositol signaling system (PIP5K1B, PIP5K1C, and PIP4K2B). Our findings suggest that DEGs encoding subunits of NADH, PRIM1, MCM3, MAPK1, STAT3, RAF1, and JAK1 might be associated with the development of lung adenocarcinoma.
    [Show full text]
  • Analyzing the Function of TRAP1 in Models of Parkinson's Disease
    Analyzing the function of TRAP1 in models of Parkinson’s disease Von der Fakultät für Mathematik, Informatik und Naturwissenschaften der RWTH Aachen University zur Erlangung des akademischen Grades einer Doktorin der Naturwissenschaften genehmigte Dissertation vorgelegt von Li Zhang aus Changchun, Jilin (China) Berichter: Universitätsprofessor Dr. med. Jörg B. Schulz Universitätsprofessor Dr. rer. nat. Marc Spehr Tag der mündlichen Prüfung: 29.01.2016 Diese Dissertation ist auf den Internetseiten der Universitätsbibliothek online verfügbar. Eidesstattliche Versicherung ___________________________Zhang, Li ___________________________ Name, Vorname Matrikelnummer (freiwillige Angabe) Ich versichere hiermit an Eides Statt, dass ich die vorliegende Arbeit/Bachelorarbeit/ Masterarbeit* mit dem Titel __________________________________________________________________________Analyzing the function of TRAP1 in models of Parkinson’s disease __________________________________________________________________________Uebersetzung: Analyse der TRAP1-Funktion in Modellen fuer Morbus Parkinson __________________________________________________________________________ selbständig und ohne unzulässige fremde Hilfe erbracht habe. Ich habe keine anderen als die angegebenen Quellen und Hilfsmittel benutzt. Für den Fall, dass die Arbeit zusätzlich auf einem Datenträger eingereicht wird, erkläre ich, dass die schriftliche und die elektronische Form vollständig übereinstimmen. Die Arbeit hat in gleicher oder ähnlicher Form noch keiner Prüfungsbehörde vorgelegen.
    [Show full text]
  • Electron Transport Chain Activity Is a Predictor and Target for Venetoclax Sensitivity in Multiple Myeloma
    ARTICLE https://doi.org/10.1038/s41467-020-15051-z OPEN Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma Richa Bajpai1,7, Aditi Sharma 1,7, Abhinav Achreja2,3, Claudia L. Edgar1, Changyong Wei1, Arusha A. Siddiqa1, Vikas A. Gupta1, Shannon M. Matulis1, Samuel K. McBrayer 4, Anjali Mittal3,5, Manali Rupji 6, Benjamin G. Barwick 1, Sagar Lonial1, Ajay K. Nooka 1, Lawrence H. Boise 1, Deepak Nagrath2,3,5 & ✉ Mala Shanmugam 1 1234567890():,; The BCL-2 antagonist venetoclax is highly effective in multiple myeloma (MM) patients exhibiting the 11;14 translocation, the mechanistic basis of which is unknown. In evaluating cellular energetics and metabolism of t(11;14) and non-t(11;14) MM, we determine that venetoclax-sensitive myeloma has reduced mitochondrial respiration. Consistent with this, low electron transport chain (ETC) Complex I and Complex II activities correlate with venetoclax sensitivity. Inhibition of Complex I, using IACS-010759, an orally bioavailable Complex I inhibitor in clinical trials, as well as succinate ubiquinone reductase (SQR) activity of Complex II, using thenoyltrifluoroacetone (TTFA) or introduction of SDHC R72C mutant, independently sensitize resistant MM to venetoclax. We demonstrate that ETC inhibition increases BCL-2 dependence and the ‘primed’ state via the ATF4-BIM/NOXA axis. Further, SQR activity correlates with venetoclax sensitivity in patient samples irrespective of t(11;14) status. Use of SQR activity in a functional-biomarker informed manner may better select for MM patients responsive to venetoclax therapy. 1 Department of Hematology and Medical Oncology, Winship Cancer Institute, School of Medicine, Emory University, Atlanta, GA, USA.
    [Show full text]
  • Bayesian Hidden Markov Tree Models for Clustering Genes with Shared Evolutionary History
    Submitted to the Annals of Applied Statistics arXiv: arXiv:0000.0000 BAYESIAN HIDDEN MARKOV TREE MODELS FOR CLUSTERING GENES WITH SHARED EVOLUTIONARY HISTORY By Yang Liy,{,∗, Shaoyang Ningy,∗, Sarah E. Calvoz,x,{, Vamsi K. Moothak,z,x,{ and Jun S. Liuy Harvard Universityy, Broad Institutez, Harvard Medical Schoolx, Massachusetts General Hospital{, and Howard Hughes Medical Institutek Determination of functions for poorly characterized genes is cru- cial for understanding biological processes and studying human dis- eases. Functionally associated genes are often gained and lost together through evolution. Therefore identifying co-evolution of genes can predict functional gene-gene associations. We describe here the full statistical model and computational strategies underlying the orig- inal algorithm CLustering by Inferred Models of Evolution (CLIME 1.0) recently reported by us [Li et al., 2014]. CLIME 1.0 employs a mixture of tree-structured hidden Markov models for gene evolution process, and a Bayesian model-based clustering algorithm to detect gene modules with shared evolutionary histories (termed evolutionary conserved modules, or ECMs). A Dirichlet process prior was adopted for estimating the number of gene clusters and a Gibbs sampler was developed for posterior sampling. We further developed an extended version, CLIME 1.1, to incorporate the uncertainty on the evolution- ary tree structure. By simulation studies and benchmarks on real data sets, we show that CLIME 1.0 and CLIME 1.1 outperform traditional methods that use simple metrics (e.g., the Hamming distance or Pear- son correlation) to measure co-evolution between pairs of genes. 1. Introduction. The human genome encodes more than 20,000 protein- coding genes, of which a large fraction do not have annotated function to date [Galperin and Koonin, 2010].
    [Show full text]
  • Mitochondrial Structure and Bioenergetics in Normal and Disease Conditions
    International Journal of Molecular Sciences Review Mitochondrial Structure and Bioenergetics in Normal and Disease Conditions Margherita Protasoni 1 and Massimo Zeviani 1,2,* 1 Mitochondrial Biology Unit, The MRC and University of Cambridge, Cambridge CB2 0XY, UK; [email protected] 2 Department of Neurosciences, University of Padova, 35128 Padova, Italy * Correspondence: [email protected] Abstract: Mitochondria are ubiquitous intracellular organelles found in almost all eukaryotes and involved in various aspects of cellular life, with a primary role in energy production. The interest in this organelle has grown stronger with the discovery of their link to various pathologies, including cancer, aging and neurodegenerative diseases. Indeed, dysfunctional mitochondria cannot provide the required energy to tissues with a high-energy demand, such as heart, brain and muscles, leading to a large spectrum of clinical phenotypes. Mitochondrial defects are at the origin of a group of clinically heterogeneous pathologies, called mitochondrial diseases, with an incidence of 1 in 5000 live births. Primary mitochondrial diseases are associated with genetic mutations both in nuclear and mitochondrial DNA (mtDNA), affecting genes involved in every aspect of the organelle function. As a consequence, it is difficult to find a common cause for mitochondrial diseases and, subsequently, to offer a precise clinical definition of the pathology. Moreover, the complexity of this condition makes it challenging to identify possible therapies or drug targets. Keywords: ATP production; biogenesis of the respiratory chain; mitochondrial disease; mi-tochondrial electrochemical gradient; mitochondrial potential; mitochondrial proton pumping; mitochondrial respiratory chain; oxidative phosphorylation; respiratory complex; respiratory supercomplex Citation: Protasoni, M.; Zeviani, M.
    [Show full text]
  • Coexpression Networks Based on Natural Variation in Human Gene Expression at Baseline and Under Stress
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations Fall 2010 Coexpression Networks Based on Natural Variation in Human Gene Expression at Baseline and Under Stress Renuka Nayak University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Computational Biology Commons, and the Genomics Commons Recommended Citation Nayak, Renuka, "Coexpression Networks Based on Natural Variation in Human Gene Expression at Baseline and Under Stress" (2010). Publicly Accessible Penn Dissertations. 1559. https://repository.upenn.edu/edissertations/1559 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/1559 For more information, please contact [email protected]. Coexpression Networks Based on Natural Variation in Human Gene Expression at Baseline and Under Stress Abstract Genes interact in networks to orchestrate cellular processes. Here, we used coexpression networks based on natural variation in gene expression to study the functions and interactions of human genes. We asked how these networks change in response to stress. First, we studied human coexpression networks at baseline. We constructed networks by identifying correlations in expression levels of 8.9 million gene pairs in immortalized B cells from 295 individuals comprising three independent samples. The resulting networks allowed us to infer interactions between biological processes. We used the network to predict the functions of poorly-characterized human genes, and provided some experimental support. Examining genes implicated in disease, we found that IFIH1, a diabetes susceptibility gene, interacts with YES1, which affects glucose transport. Genes predisposing to the same diseases are clustered non-randomly in the network, suggesting that the network may be used to identify candidate genes that influence disease susceptibility.
    [Show full text]
  • Accessory Subunits Are Integral for Assembly and Function of Human Mitochondrial Complex I
    Accessory subunits are integral for assembly and function of human mitochondrial complex I David A. Stroud1*, Elliot E. Surgenor1, Luke E. Formosa1,2, Boris Reljic2†, Ann E. Frazier3,4, Marris G. Dibley1, Laura D. Osellame1, Tegan Stait3, Traude H. Beilharz1, David R. Thorburn3-5, Agus Salim6, Michael T. Ryan1* 1Department of Biochemistry and Molecular Biology, Monash Biomedicine Discovery Institute, Monash University, 3800, Melbourne, Australia. 2Department of Biochemistry and Genetics, La Trobe Institute for Molecular Science, La Trobe University 3086, Melbourne, Australia. 3Murdoch Childrens Research Institute, Royal Children’s Hospital, Melbourne 3052, Australia 4Department of Pediatrics, University of Melbourne, Melbourne 3052, Australia. 5Victorian Clinical Genetics Services, Royal Children’s Hospital 3052, Melbourne, Australia. 6Department of Mathematics and Statistics, La Trobe University 3086, Melbourne Australia. *Correspondence to: [email protected] and [email protected] †Current address: Walter and Eliza Hall Institute of Medical Research, Parkville, Melbourne, Victoria 3052, Australia Complex I (NADH:ubiquinone oxidoreductase) is the first enzyme of the mitochondrial respiratory chain (RC) and is composed of 44 different subunits in humans, making it one of the largest known multi-subunit membrane protein complexes1. Complex I exists in supercomplex forms with RC complexes III and IV, which are together required for the generation of a transmembrane proton gradient used for the synthesis of ATP2. Complex I is also a major source of damaging reactive oxygen species and its dysfunction is associated with mitochondrial disease, Parkinson’s disease and aging3-5. Bacterial and human complex I share 14 core subunits essential for enzymatic function, however the role and requirement of the remaining 31 human accessory subunits is unclear1,6.
    [Show full text]
  • Reveals of Candidate Active Ingredients in Justicia and Its Anti-Thrombotic Action of Mechanism Based on Network Pharmacology Ap
    www.nature.com/scientificreports OPEN Reveals of candidate active ingredients in Justicia and its anti‑thrombotic action of mechanism based on network pharmacology approach and experimental validation Zongchao Hong1,5, Ting Zhang2,5, Ying Zhang1, Zhoutao Xie1, Yi Lu1, Yunfeng Yao1, Yanfang Yang1,3,4*, Hezhen Wu1,3,4* & Bo Liu1,3* Thrombotic diseases seriously threaten human life. Justicia, as a common Chinese medicine, is usually used for anti‑infammatory treatment, and further studies have found that it has an inhibitory efect on platelet aggregation. Therefore, it can be inferred that Justicia can be used as a therapeutic drug for thrombosis. This work aims to reveal the pharmacological mechanism of the anti‑thrombotic efect of Justicia through network pharmacology combined with wet experimental verifcation. During the analysis, 461 compound targets were predicted from various databases and 881 thrombus‑related targets were collected. Then, herb‑compound‑target network and protein–protein interaction network of disease and prediction targets were constructed and cluster analysis was applied to further explore the connection between the targets. In addition, Gene Ontology (GO) and pathway (KEGG) enrichment were used to further determine the association between target proteins and diseases. Finally, the expression of hub target proteins of the core component and the anti‑thrombotic efect of Justicia’s core compounds were verifed by experiments. In conclusion, the core bioactive components, especially justicidin D, can reduce thrombosis by regulating F2, MMP9, CXCL12, MET, RAC1, PDE5A, and ABCB1. The combination of network pharmacology and the experimental research strategies proposed in this paper provides a comprehensive method for systematically exploring the therapeutic mechanism of multi‑component medicine.
    [Show full text]
  • Autocrine IFN Signaling Inducing Profibrotic Fibroblast Responses by a Synthetic TLR3 Ligand Mitigates
    Downloaded from http://www.jimmunol.org/ by guest on September 28, 2021 Inducing is online at: average * The Journal of Immunology published online 16 August 2013 from submission to initial decision 4 weeks from acceptance to publication http://www.jimmunol.org/content/early/2013/08/16/jimmun ol.1300376 A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Autocrine IFN Signaling Feng Fang, Kohtaro Ooka, Xiaoyong Sun, Ruchi Shah, Swati Bhattacharyya, Jun Wei and John Varga J Immunol Submit online. Every submission reviewed by practicing scientists ? is published twice each month by http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://www.jimmunol.org/content/suppl/2013/08/20/jimmunol.130037 6.DC1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 28, 2021. Published August 16, 2013, doi:10.4049/jimmunol.1300376 The Journal of Immunology A Synthetic TLR3 Ligand Mitigates Profibrotic Fibroblast Responses by Inducing Autocrine IFN Signaling Feng Fang,* Kohtaro Ooka,* Xiaoyong Sun,† Ruchi Shah,* Swati Bhattacharyya,* Jun Wei,* and John Varga* Activation of TLR3 by exogenous microbial ligands or endogenous injury-associated ligands leads to production of type I IFN.
    [Show full text]
  • Systematic Proteome and Proteostasis Profiling in Human Trisomy
    ARTICLE DOI: 10.1038/s41467-017-01422-6 OPEN Systematic proteome and proteostasis profiling in human Trisomy 21 fibroblast cells Yansheng Liu 1, Christelle Borel2,LiLi3, Torsten Müller1, Evan G. Williams1, Pierre-Luc Germain4, Marija Buljan1, Tatjana Sajic1, Paul J. Boersema5, Wenguang Shao1, Marco Faini1, Giuseppe Testa4,6, Andreas Beyer 3, Stylianos E. Antonarakis2,7 & Ruedi Aebersold 1,8 Down syndrome (DS) is mostly caused by a trisomy of the entire Chromosome 21 (Trisomy 21, T21). Here, we use SWATH mass spectrometry to quantify protein abundance and protein turnover in fibroblasts from a monozygotic twin pair discordant for T21, and to profile protein expression in 11 unrelated DS individuals and matched controls. The integration of the steady- state and turnover proteomic data indicates that protein-specific degradation of members of stoichiometric complexes is a major determinant of T21 gene dosage outcome, both within and between individuals. This effect is not apparent from genomic and transcriptomic data. The data also reveal that T21 results in extensive proteome remodeling, affecting proteins encoded by all chromosomes. Finally, we find broad, organelle-specific post-transcriptional effects such as significant downregulation of the mitochondrial proteome contributing to T21 hallmarks. Overall, we provide a valuable proteomic resource to understand the origin of DS phenotypic manifestations. 1 Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, 8093 Zurich, Switzerland. 2 Department of Genetic Medicine and Development, University of Geneva Medical School, and University Hospitals of Geneva, 1211 Geneva, Switzerland. 3 Cellular Networks and Systems Biology, University of Cologne, CECAD, University of Cologne, 50931 Cologne, Germany. 4 Department of Experimental Oncology, European Institute of Oncology, 20139 Milan, Italy.
    [Show full text]